MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
21/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinMTNB / S&P 22.40% / 15.20% |
LoseMTNB / S&P MTNB unavailable / 15.00% |
LoseMTNB / S&P -69.92% / 50.40% |
| 2026-Q10/3 |
LoseMTNB / S&P -14.68% / -4.33% |
LoseMTNB / S&P MTNB unavailable / 11.30% |
LoseMTNB / S&P -50.37% / 27.70% |
| 2025-Q40/3 |
LoseMTNB / S&P -68.99% / 2.65% |
LoseMTNB / S&P MTNB unavailable / 9.00% |
LoseMTNB / S&P -59.76% / 13.40% |
| 2025-Q31/3 |
WinMTNB / S&P 112.36% / 8.12% |
LoseMTNB / S&P MTNB unavailable / 4.61% |
LoseMTNB / S&P -24.56% / 13.45% |
| 2025-Q21/3 |
WinMTNB / S&P 71.15% / 10.94% |
LoseMTNB / S&P MTNB unavailable / 4.83% |
LoseMTNB / S&P -23.73% / 10.63% |
| 2025-Q11/3 |
WinMTNB / S&P 1.96% / -4.27% |
LoseMTNB / S&P MTNB unavailable / 4.98% |
LoseMTNB / S&P 0.75% / 10.57% |
| 2024-Q41/3 |
LoseMTNB / S&P -85.59% / 2.41% |
LoseMTNB / S&P MTNB unavailable / 5.25% |
WinMTNB / S&P 88.01% / 6.15% |
| 2024-Q31/3 |
LoseMTNB / S&P -55.19% / 5.89% |
LoseMTNB / S&P MTNB unavailable / 5.89% |
WinMTNB / S&P 210.20% / 6.11% |
| 2024-Q21/3 |
LoseMTNB / S&P -41.70% / 4.28% |
LoseMTNB / S&P MTNB unavailable / 5.38% |
WinMTNB / S&P 4536.36% / 5.12% |
| 2024-Q12/3 |
WinMTNB / S&P 25.46% / 10.56% |
LoseMTNB / S&P MTNB unavailable / 5.71% |
WinMTNB / S&P 3518.18% / 5.59% |
| 2023-Q41/3 |
WinMTNB / S&P 66.15% / 11.69% |
LoseMTNB / S&P MTNB unavailable / 6.81% |
LoseMTNB / S&P MTNB unavailable / 7.78% |
| 2023-Q30/3 |
LoseMTNB / S&P -63.89% / -3.27% |
LoseMTNB / S&P MTNB unavailable / 7.52% |
LoseMTNB / S&P MTNB unavailable / -5.03% |
| 2023-Q20/3 |
LoseMTNB / S&P -23.40% / 8.74% |
LoseMTNB / S&P MTNB unavailable / 9.50% |
LoseMTNB / S&P MTNB unavailable / -8.57% |
| 2023-Q10/3 |
LoseMTNB / S&P -6.00% / 7.50% |
LoseMTNB / S&P MTNB unavailable / 10.77% |
LoseMTNB / S&P MTNB unavailable / -15.69% |
| 2022-Q40/3 |
LoseMTNB / S&P -21.38% / 7.56% |
LoseMTNB / S&P MTNB unavailable / 11.88% |
LoseMTNB / S&P MTNB unavailable / -17.99% |
| 2022-Q30/3 |
LoseMTNB / S&P -19.49% / -4.88% |
LoseMTNB / S&P MTNB unavailable / 13.47% |
LoseMTNB / S&P MTNB unavailable / -1.41% |
| 2022-Q21/3 |
WinMTNB / S&P -1.74% / -16.10% |
LoseMTNB / S&P MTNB unavailable / 13.71% |
LoseMTNB / S&P MTNB unavailable / 11.04% |
| 2022-Q10/3 |
LoseMTNB / S&P -20.40% / -4.60% |
LoseMTNB / S&P MTNB unavailable / 15.97% |
LoseMTNB / S&P MTNB unavailable / 42.23% |
| 2021-Q40/3 |
LoseMTNB / S&P -22.31% / 11.03% |
LoseMTNB / S&P MTNB unavailable / 15.00% |
LoseMTNB / S&P MTNB unavailable / 96.40% |
| 2021-Q31/3 |
WinMTNB / S&P 67.74% / 0.58% |
LoseMTNB / S&P MTNB unavailable / 10.77% |
LoseMTNB / S&P MTNB unavailable / 69.42% |
| 2021-Q20/3 |
LoseMTNB / S&P -26.19% / 8.55% |
LoseMTNB / S&P MTNB unavailable / 6.58% |
LoseMTNB / S&P MTNB unavailable / 51.81% |
| 2021-Q10/3 |
LoseMTNB / S&P -22.79% / 6.17% |
LoseMTNB / S&P MTNB unavailable / -1.06% |
LoseMTNB / S&P MTNB unavailable / 7.39% |
| 2020-Q41/3 |
WinMTNB / S&P 77.55% / 12.15% |
LoseMTNB / S&P MTNB unavailable / -3.72% |
LoseMTNB / S&P MTNB unavailable / -33.42% |
| 2020-Q30/3 |
LoseMTNB / S&P -0.91% / 8.93% |
LoseMTNB / S&P MTNB unavailable / -2.04% |
LoseMTNB / S&P MTNB unavailable / -27.10% |
| 2020-Q21/3 |
WinMTNB / S&P 28.83% / 20.54% |
LoseMTNB / S&P MTNB unavailable / -0.46% |
LoseMTNB / S&P MTNB unavailable / -27.11% |
| 2020-Q10/3 |
LoseMTNB / S&P -73.57% / -19.60% |
LoseMTNB / S&P MTNB unavailable / 3.47% |
LoseMTNB / S&P MTNB unavailable / -14.75% |
| 2019-Q41/3 |
WinMTNB / S&P 259.75% / 9.07% |
LoseMTNB / S&P MTNB unavailable / 5.36% |
LoseMTNB / S&P MTNB unavailable / 2.99% |
| 2019-Q30/3 |
LoseMTNB / S&P -26.37% / 1.70% |
LoseMTNB / S&P MTNB unavailable / 5.02% |
LoseMTNB / S&P MTNB unavailable / 0.21% |
| 2019-Q20/3 |
LoseMTNB / S&P -21.38% / 4.30% |
LoseMTNB / S&P MTNB unavailable / 6.64% |
LoseMTNB / S&P MTNB unavailable / 8.65% |
| 2019-Q11/3 |
WinMTNB / S&P 83.19% / 13.65% |
LoseMTNB / S&P MTNB unavailable / 8.12% |
LoseMTNB / S&P MTNB unavailable / 14.29% |
| 2018-Q40/3 |
LoseMTNB / S&P -35.33% / -13.52% |
LoseMTNB / S&P MTNB unavailable / 9.05% |
LoseMTNB / S&P MTNB unavailable / 18.23% |
| 2018-Q31/3 |
WinMTNB / S&P 111.98% / 7.71% |
LoseMTNB / S&P MTNB unavailable / 10.21% |
LoseMTNB / S&P MTNB unavailable / 19.06% |
| 2018-Q21/3 |
LoseMTNB / S&P -43.27% / 3.43% |
WinMTNB / S&P 250.00% / 9.03% |
LoseMTNB / S&P MTNB unavailable / 14.46% |
| 2018-Q11/3 |
LoseMTNB / S&P -34.05% / -0.76% |
WinMTNB / S&P 999.97% / 7.68% |
LoseMTNB / S&P MTNB unavailable / 12.46% |
| 2017-Q40/3 |
LoseMTNB / S&P -12.12% / 6.64% |
LoseMTNB / S&P MTNB unavailable / 7.03% |
LoseMTNB / S&P MTNB unavailable / 13.82% |
| 2017-Q30/3 |
LoseMTNB / S&P -21.89% / 4.48% |
LoseMTNB / S&P MTNB unavailable / 5.68% |
LoseMTNB / S&P MTNB unavailable / 17.57% |
| 2017-Q20/3 |
LoseMTNB / S&P -38.99% / 3.09% |
LoseMTNB / S&P 0.03% / 4.83% |
LoseMTNB / S&P MTNB unavailable / 17.74% |
| 2017-Q11/3 |
WinMTNB / S&P 97.86% / 6.07% |
LoseMTNB / S&P -89.06% / 3.67% |
LoseMTNB / S&P MTNB unavailable / 13.32% |
| 2016-Q40/3 |
LoseMTNB / S&P -12.50% / 3.82% |
LoseMTNB / S&P -100.00% / 2.09% |
LoseMTNB / S&P MTNB unavailable / 7.05% |
| 2016-Q31/3 |
WinMTNB / S&P 102.53% / 3.85% |
LoseMTNB / S&P -100.00% / 0.20% |
LoseMTNB / S&P MTNB unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | MTNB total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -89.01% | 20.78% |
| Annualized return | -89.01% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | MTNB total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.51% | 83.14% |
| Annualized return | -65.47% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | MTNB total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.49% | 319.30% |
| Annualized return | -40.98% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |